Interim Analysis of Real-World Effectiveness and Usage of Recombinant Factor IX Fc for Surgical Haemostasis from the 24-Month Prospective, Non-Interventional B-MORE Study
2024 - 2024
Coauthor on poster presentation at European Association for Haemophilia and Allied Disorders Meeting Frankfurt February 2024.
A single centre assessment of the frequency and clinical relevance of discrepant factor VIII assays both in persons without a disorder of haemostasis and in those with haemophilia A
2024 - 2024
Lead author on poster presentation at European Society for Haemophilia and Allied Disorders Meeting, Frankfurt, February 2024.
Management of acute leukaemia and pregnancy outcomes in patients with current or previous leukaemia
2024 - 2024
Management of acute leukaemia and pregnancy outcomes in patients with current or previous leukaemia
Dr Lukas Pitel, Dr Matthew Northgraves, Prof. Judith Cohen, Dr Chao Huang, Mr. John Turgoose, Dr Sahra Ali, Prof. Mhairi Copland, Panagiotis D. Kottaridis, Dr David Allsup
ePoster presentation at British Society for Haematology Meeting Liverpool, April 2024.
CLL, diagnosis, treatment pathways and research
2024 - 2024
Plenary podium lecture at the CLL support association annual conference. A meeting to support persons diagnosed with CLL.
Does the Life Expectancy of Elderly CLL patients receiving upfront Targeted Agents approach the Life Expectancy of the General Population?
2023 - 2023
Oral presentation at the International Workshop in CLL, Boston, USA.
Stopping ibrutinib after 6 years of continuous exposure results in decreased or stable CLL levels for at least a year in most patients, providing further support for the STATIC trial evaluating intermittent BTKi treatment.
2023 - 2023
Co-author on the above oral presentation at the International Workshop for CLL, Boston, USA.
Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: Report of the Phase III UK NCRI FLAIR study
2023 - 2023
Co-author on the above oral presentation at the Amercian Society Haematology, San Diego, December 2023.
Using peripheral blood (PB) measurable residual disease (MRD) levels to predict <0.01% bone marrow disease (BM uMRD4): identification of effective PB targets for CLL treatment cessation in the ibrutinib+venetoclax arm of the FLAIR trial
2023 - 2023
Co-author on the above presentation at the American Society of Haematology meeting, San Diego, USA, December 2023.
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients in FLAIR Study with previously untreated chronic lymphocytic leukaemia: Assessment of mutational landscape of patients at baseline and prognostic impact
2023 - 2023
Co-author on above poster presentation at the American Society of Haematology Meeting San Diego USA, December 2023.
Targeted Agents in CLL: Advancements in Overall Survival Outcomes?
2023 - 2023
Co-author on the above poster presentation at the American Society of Haematology Meeting, San Diego USA, December 2023.
Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact
2023 - 2023
Co-author on the above conference presentation ,poster, at the American Society of Haematology meeting, San Diego, USA, December 2023.
The Integration of Efficacy and Safety Outcomes Identifies the Net Clinical Benefit of Targeted Agents in Upfront Therapy of Chronic Lymphocytic Leukemia: Results of Network Meta-Analysis
2022 - 2022
Conference presentation American Society of Haematology 2022
Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
2022 - 2022
Conference presentation American Society of Haematology, 2022
Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
2022 - 2022
Conference presentation American Society of Haematology 2022
P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX
2022 - 2022
Conference presentation, European Haematology Association Congress 2022.
THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL
2022 - 2022
Conference presentation European Haematology Association Congress
Biomarker Driven Antifungal Stewardship in Acute Leukaemia (BioDriveAFS)—a multicentre randomized controlled trial to assess clinical and cost effectiveness
2022 - 2022
Conference presentation, BSAC meeting, London 2022.
Sudden or Cardiac Deaths on Ibrutinib-Based Therapy were associated with a prior History of Hypertension or Cardiac Disease and the use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
2022 - 2022
Conference presentation British Society for Haematology, 2022
The impact of bacterial superantigens on T cell exhaustion in chronic lymphocytic leukemia (CLL) patients
2021 - 2021
Poster presentation at British Society for Immunology
Ten-year follow-up of 415 CLL patients treated with fludarabine cyclophosphamide-based chemoimmunotherapy in the frontline ARCTIC and ADMIRE trials, a comprehensive assessment of prognostic factors.
2021 - 2021
Poster presentation at European Haematology Association
B-MORE, Baseline Analysis from a 24-month Prospective, Non-interventional, Multicentre Study on Real-world Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B
2021 - 2021
Poster presentation at International Society for Thrombosis and Haemostasis
Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial
2021 - 2021
Presentation at American Society of Haematology
Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
2021 - 2021
Presentation at American Society of Haematology
A single centre study to assess delivery of vaccination advice to patients with chronic lymphocytic leukaemia
2021 - 2021
British Society of Haematology Meeting, virtual
Splenectomy in immune thrombocytopenia: do changing treatment patterns for ITP affect outcome? Data from the UK ITP registry
2020 - 2020
Co-author on above presentation at BSH 2020
Btk inhibitors Ibrutinib and Acalabrutinib impair FcγRIIA-mediated responses of healthy donor platelets and Chronic Lymphocytic Leukaemia platelets to bacteria.
2020 - 2020
Co-author on above poster presentation at BSH 2020.
Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens
2020 - 2020
Poster presentation American Society for Haematology
Andrea GS Pepper, PhD1*, Antonella Zucchetto, PhD2*, Kevin Norris, PhD3*, Erika Tissino, PhD4*, Jerry Polesel5*, Zarni Soe6*, David Allsup7*, Anna Hockaday8*, Pei Loo Ow9*, Peter Hillmen, MBChB, PhD10*, Andrew Rawstron, PhD11*, Daniel Catovsky, MD, FRCP12, Riccardo Bomben, PhD2*, Duncan M Baird, PhD13*, Christopher Fegan14*, Valter Gattei, MD15 and Chris Pepper, BSc, PhD16
Bruton's Tyrosine Kinase Inhibitors Impair Fcγriia-Mediated Responses of Healthy Donor Platelets and Chronic Lymphocytic Leukaemia Derived Platelets to Bacteria
2020 - 2020
1748 Bruton's Tyrosine Kinase Inhibitors Impair Fcγriia-Mediated Responses of Healthy Donor Platelets and Chronic Lymphocytic Leukaemia Derived Platelets to Bacteria
Program: Oral and Poster Abstracts
Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster II
Hematology Disease Topics & Pathways:
Leukemia, Diseases, CLL, Therapies, Biological Processes, Lymphoid Malignancies, Clinically relevant, immune mechanism, pathways
Sunday, December 6, 2020, 7:00 AM-3:30 PM
Leigh Naylor-Adamson1*, Zoe Booth2*, Simon Hart3*, Russell Patmore4, Sujoy Khan5*, David Allsup6* and Monica Arman6*
1Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Owston Ferry, ENG, United Kingdom
2Centre for Atherothrombosis and Metabolic Disease, University of Hull, Hull, ENG, United Kingdom
3Respiratory Research Group, Hull York Medical School, Hull, ENG, United Kingdom
4Department of Haematology, Hull and East Yorkshire Hospitals NHS Trust, Hull, ENG, United Kingdom
5Department of Immunology & Allergy, Hull and East Yorkshire Hospitals NHS Trust, Hull, ENG, United Kingdom
6Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, ENG, United Kingdom
Btk Inhibitor Ibrutinib Impairs FcγRIIa-Mediated Responses of Platelets from Healthy Donors and Chronic Lymphocytic Leukaemia Patients to Bacteria
2020 - 2020
Authors: Leigh Naylor-Adamson1, Zoe Booth1, Simon P. Hart3, David J Allsup1,4, and Mònica Arman1
Affiliations: 1Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull; 2Respiratory Research Group, Hull York Medical School, University of Hull; 3Department of Haematology, Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust.
Poster British Society Haematology Meeting 2020
Multicenter Genome Wide Association Study Identifies Constitutional Risk Alleles for Progressive Chronic Lymphocytic Leukemia
2019 - 2019
David Allsup, Wei-Yu Lin, Sarah Fordham, Nicola Sunter, Claire Elstob, Thahira Rahman, Elaine Willmore, Colin Shepherd, Gordon Strathdee, Timothy Barrow, Tryfonia Mainou-Fowler, Rachel Piddock, Helen Marr, Jonathan Wallis, Scott Marshall, Andrew Pettitt, Christopher Pepper, Christopher Fegan, Francesco Forconi, Martin JS Dyer, Sandrine Jayne, April Sellors, Anna Schuh, Pauline Robbe David Oscier, Richard S. Houlston, James Bailey, Syed Rais, Alison Bentley, Lynn Cawkwell, Peter Hillmen, Guy Pratt , James Allan.
Conference presentation, American Society for Haematology, Orlando, December 2019.
SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY
2019 - 2019
European Haematology Association Annual Congress
COSMIC, a phase II randomised study investigating the efficacy of standard or high-dose ofatumumab in combination with chemotherapy in patients with relapsed chronic lymphocytic leukaemia
2017 - 2017
Poster presentation , International Workshop Chronic Lymphocytic Leukaemia
New York
Training in safe administration of intrathecal chemotherapy – is in situ simulation the answer?: A pilot study
2015 - 2015
BMJ Simulation & Technology Enhanced Learning
New UKHCDO von Willebrand disease guidelines allow re-classification of a large proportion of adult patients and can result in de-diagnosis of patients without haemorrhagic consequences
2015 - 2015
Poster presentation British Society for Haematology Meeting